Zydus Lifesciences
Zydus Lifesciences, formerly known as Zydus Cadila, is a prominent player in the global pharmaceutical industry, headquartered in India. Founded in 1995, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Zydus Lifesciences focuses on research and development, manufacturing, and marketing of a diverse range of healthcare products, including generic medicines, biosimilars, and vaccines. With a commitment to innovation, Zydus Lifesciences has achieved significant milestones, such as the development of India's first indigenously produced DNA vaccine. The company is recognised for its robust portfolio of over 1,000 products, which cater to various therapeutic areas, making it a key player in the pharmaceutical market. Zydus Lifesciences continues to enhance its market position through strategic partnerships and a dedication to improving global health outcomes.
DitchCarbon Score
How does Zydus Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Lifesciences's score of 35 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zydus Lifesciences's reported carbon emissions
In 2023, Zydus Lifesciences reported total carbon emissions of approximately 279,068,020 kg CO2e, with Scope 1 emissions at about 44,792,270 kg CO2e, Scope 2 emissions at approximately 175,980,980 kg CO2e, and Scope 3 emissions reaching around 25,670,000 kg CO2e. This marked a slight increase from 2022, where total emissions were about 255,889,000 kg CO2e. In 2022, the company disclosed emissions of approximately 250,744,820 kg CO2e for Scope 1 and 2 combined, with Scope 1 emissions at about 59,573,850 kg CO2e and Scope 2 emissions at approximately 191,170,970 kg CO2e. The Scope 3 emissions for that year were reported at around 9,072,000 kg CO2e. Zydus Lifesciences has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to monitor and report its emissions, reflecting its engagement with climate accountability, but lacks defined strategies for significant emissions reductions at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 2,409,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,039,000 | 0,000,000 | 00,000,000 | 0,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Lifesciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
